Mobile

Safety and Efficacy of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors Including Central Nervous System Tumors

Mise à jour : Il y a 4 ans
Référence : U1111-1128-5704

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Phase 1 Part: To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cabazitaxel as a single agent in pediatric patients with recurrent or refractory solid tumors including tumors of the central nervous system. Phase 2 Part: To determine the objective response rate (complete and partial response) and the duration of response to cabazitaxel as a single agent in patients with recurrent or refractory high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG).

Critère d'inclusion

  • Cancer

Liens